aTyr Pharma

aTyr Pharma PEG

The PEG Ratio (Price/Earnings-to-Growth) of aTyr Pharma (ATYR) as of Nov 4, 2026 is -3.46. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was -1.16 — a change of 198.34% (lower).

PEG

-3.46

YoY

198.34%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of aTyr Pharma is 2025 -3.46 . PEG Ratio (Price/Earnings-to-Growth) of aTyr Pharma was 2024 -1.16 . It decreases by 198.34% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

aTyr Pharma Stock analysis

What does aTyr Pharma do? aTyr Pharma Inc is a biotechnology company based in San Diego, California. Founded in 2005, the company has gained a lot of attention in recent years for its focus on developing drugs based on proteomics, the analysis of proteins. The idea for aTyr came from the realization that there are a variety of proteins that can be used as a basis for developing new drugs. The company has developed a unique proteomics platform that allows for the identification and utilization of previously undiscovered proteins to understand biological processes and develop new drugs for diseases. aTyr specializes in the discovery and development of proteins associated with rare but difficult-to-treat diseases. This includes rare muscle diseases and lung diseases. The company collaborates closely with clinicians and scientists to advance its research and development. aTyr's business model is based on the development of new drugs based on proteomics, with a focus on rare diseases that are often neglected. The goal is to improve the quality of life for patients by developing new and innovative drugs. aTyr has various divisions, including therapeutic proteins and diagnostics. The company has a number of drugs in development targeting different diseases. This includes Resolaris, a protein focused on rare muscle diseases, and ATYR1923, developed for the treatment of lung diseases. Resolaris is a novel protein targeting rare muscle diseases such as FSHD and LGMD. It is currently being tested in clinical trials and has the potential to significantly improve the quality of life for patients with these severe conditions. The company is also developing ATYR1923, a protein for the treatment of lung diseases such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Overall, aTyr Pharma is an innovative company focused on the development of novel drugs based on proteomics. With its unique proteomics platform, the company has the potential to identify and utilize previously undiscovered proteins to understand biological processes and develop new drugs for diseases. With its various divisions, including therapeutic proteins and diagnostics, the company has the potential to improve the treatment of rare and difficult-to-treat diseases and enhance the lives of patients worldwide. aTyr Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about aTyr Pharma stock

PEG Ratio (Price/Earnings-to-Growth) of aTyr Pharma is -3.46 in 2025.

PEG Ratio (Price/Earnings-to-Growth) of aTyr Pharma changed from -1.16 to -3.46, representing a 198.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) aTyr Pharma since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s aTyr Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — aTyr Pharma

All Key Metrics — aTyr Pharma